- Published at
- by raskmedia.com.au
positive
positive
CSL share price: why investors like healthcare shares
Is the CSL Ltd (ASX:CSL) share price cheap? Here are 3 reasons you might want to consider CSL shares.
News for CSL Limited (CSL.AX)
- Published at
- by raskmedia.com.au
positivepositiveCSL and Pro Medicus Ltd: 2 ASX shares to dig into
The CSL Ltd (ASX:CSL) share price and Pro Medicus Ltd (ASX:PME) share price are in focus in 2025. Here's how you could put a value on them.- Published at
- by raskmedia.com.au
positivepositiveA deep dive into CSL shares
Is the CSL Ltd (ASX:CSL) share price undervalued? Here are 3 reasons you might want to consider CSL shares.- Published at
- by raskmedia.com.au
positivepositiveJHX shares: your next growth investment?
The James Hardie Industries plc (ASX:JHX) share price and CSL Ltd (ASX:CSL) share price are in focus in 2025. Here's how you could put a value on them.- Published at
- by raskmedia.com.au
positivepositiveA quick way to value the CSL share price
Want to value the CSL Ltd (ASX:CSL) share price? Here are 6 key metrics you need to consider.- Published at
- by raskmedia.com.au
positivepositiveAre CSL shares or PME shares better value in 2025?
The CSL Ltd (ASX:CSL) share price and Pro Medicus Ltd (ASX:PME) share price are in focus in 2025. Here's how you could put a value on them.- Published at
- by raskmedia.com.au
positivepositiveCSL share price: why investors like healthcare shares
Is the CSL Ltd (ASX:CSL) share price cheap? Here are 3 reasons you might want to consider CSL shares.- Published at
- by raskmedia.com.au
positivepositiveI’m keeping an eye on JHX shares in 2025
The James Hardie Industries plc (ASX:JHX) share price and CSL Ltd (ASX:CSL) share price are in focus in 2025. Here's how you could put a value on them.- Published at
- by gurufocus.com
positivepositiveEngland's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
PR NewswireST. GALLEN, Switzerland, May 23, 2025 First non-immunosuppressive dual-action therapy recommended by NICE for eligible patients with IgA nephrop- Published at
- by raskmedia.com.au
positivepositiveA quick way to value the CSL share price
Want to value the CSL Ltd (ASX:CSL) share price? Here are 6 key metrics you need to consider.- Published at
- by raskmedia.com.au
positivepositiveCSL and Pro Medicus Ltd: 2 ASX shares to dig into
The CSL Ltd (ASX:CSL) share price and Pro Medicus Ltd (ASX:PME) share price are in focus in 2025. Here's how you could put a value on them.- Published at
- by raskmedia.com.au
positivepositiveA deep dive into CSL shares
Is the CSL Ltd (ASX:CSL) share price undervalued? Here are 3 reasons you might want to consider CSL shares.- Published at
- by raskmedia.com.au
positivepositiveJHX shares: your next growth investment?
The James Hardie Industries plc (ASX:JHX) share price and CSL Ltd (ASX:CSL) share price are in focus in 2025. Here's how you could put a value on them.- Published at
- by raskmedia.com.au
positivepositiveA quick way to value the CSL share price
Want to value the CSL Ltd (ASX:CSL) share price? Here are 6 key metrics you need to consider.- Published at
- by raskmedia.com.au
positivepositiveAre CSL shares or PME shares better value in 2025?
The CSL Ltd (ASX:CSL) share price and Pro Medicus Ltd (ASX:PME) share price are in focus in 2025. Here's how you could put a value on them.- Published at
- by raskmedia.com.au
positivepositiveCSL share price: why investors like healthcare shares
Is the CSL Ltd (ASX:CSL) share price cheap? Here are 3 reasons you might want to consider CSL shares.- Published at
- by raskmedia.com.au
positivepositiveI’m keeping an eye on JHX shares in 2025
The James Hardie Industries plc (ASX:JHX) share price and CSL Ltd (ASX:CSL) share price are in focus in 2025. Here's how you could put a value on them.- Published at
- by smallcaps.com.au
mixedmixed- Published at
- by raskmedia.com.au
positivepositiveA quick way to value the CSL share price
Want to value the CSL Ltd (ASX:CSL) share price? Here are 6 key metrics you need to consider.- Published at
- by gurufocus.com
positivepositiveTravere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy
Travere Therapeutics, Inc., (NASDAQ: TVTX) and CSL Vifor are pleased to announce that the European Commission has approved the conversion of the conditional ma